Enorama Pharma AB (ST:ERMA) — Market Cap & Net Worth
Market Cap & Net Worth: Enorama Pharma AB (ERMA)
Enorama Pharma AB (ST:ERMA) has a market capitalization of $2.25 Million (Skr20.88 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #29565 globally and #681 in its home market, demonstrating a 4.09% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Enorama Pharma AB's stock price Skr0.28 by its total outstanding shares 74588682 (74.59 Million). Analyse Enorama Pharma AB cash conversion from operations to see how efficiently the company converts income to cash.
Enorama Pharma AB Market Cap History: 2016 to 2026
Enorama Pharma AB's market capitalization history from 2016 to 2026. Data shows change from $70.67 Million to $2.25 Million (-28.49% CAGR).
Index Memberships
Enorama Pharma AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$14.99 Billion | 0.01% | #226 of 281 |
Weight: Enorama Pharma AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Enorama Pharma AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Enorama Pharma AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.60x
Enorama Pharma AB's market cap is 5.60 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $70.67 Million | $3.99 Million | -$7.84 Million | 17.71x | N/A |
| 2017 | $628.16 Million | $1.57 Million | -$8.76 Million | 399.37x | N/A |
| 2018 | $471.98 Million | $5.26 Million | -$16.34 Million | 89.80x | N/A |
| 2019 | $325.09 Million | $7.61 Million | -$24.72 Million | 42.71x | N/A |
| 2020 | $265.69 Million | $2.15 Million | -$23.90 Million | 123.81x | N/A |
| 2021 | $178.60 Million | $11.04 Million | -$28.54 Million | 16.18x | N/A |
| 2022 | $29.30 Million | $6.85 Million | -$41.78 Million | 4.28x | N/A |
| 2023 | $24.88 Million | $1.36 Million | -$44.61 Million | 18.32x | N/A |
| 2024 | $26.97 Million | $15.77 Million | -$43.81 Million | 1.71x | N/A |
| 2025 | $15.33 Million | $2.74 Million | -$75.14 Million | 5.60x | N/A |
Competitor Companies of ERMA by Market Capitalization
Companies near Enorama Pharma AB in the global market cap rankings as of May 4, 2026.
Key companies related to Enorama Pharma AB by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Enorama Pharma AB Historical Marketcap From 2016 to 2026
Between 2016 and today, Enorama Pharma AB's market cap moved from $70.67 Million to $ 2.25 Million, with a yearly change of -28.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr2.25 Million | -85.34% |
| 2025 | Skr15.33 Million | -43.15% |
| 2024 | Skr26.97 Million | +8.39% |
| 2023 | Skr24.88 Million | -15.07% |
| 2022 | Skr29.30 Million | -83.60% |
| 2021 | Skr178.60 Million | -32.78% |
| 2020 | Skr265.69 Million | -18.27% |
| 2019 | Skr325.09 Million | -31.12% |
| 2018 | Skr471.98 Million | -24.86% |
| 2017 | Skr628.16 Million | +788.89% |
| 2016 | Skr70.67 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Enorama Pharma AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.25 Million USD |
| MoneyControl | $2.25 Million USD |
| MarketWatch | $2.25 Million USD |
| marketcap.company | $2.25 Million USD |
| Reuters | $2.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.